Abstract
Two new studies report the identification of activating ESR1 gene mutations in aromatase inhibitor-resistant metastatic breast cancers. This insight into therapeutic resistance suggests new approaches that may be useful in the management of endocrine-resistant breast cancer.
MeSH terms
-
Animals
-
Antineoplastic Agents, Hormonal / therapeutic use*
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / pathology*
-
Drug Resistance, Neoplasm / genetics*
-
Estrogen Receptor alpha / genetics*
-
Female
-
Humans
-
Mutation, Missense*
-
Protein Interaction Domains and Motifs / genetics*
Substances
-
Antineoplastic Agents, Hormonal
-
ESR1 protein, human
-
Estrogen Receptor alpha